The role of cytokines in the pathogenesis and staging of Trypanosoma brucei rhodesiense sleeping sickness

Allergy, Asthma and Clinical Immunology

Volumn 12, Issue 1, 2016, Pages

  Kato, Charles D ^a   Matovu, Enock ^a   Mugasa, Claire M ^a   Nanteza, Ann ^a   Alibu, Vincent P ^a  

^a MAKERERE UNIVERSITY   (Uganda)

Author keywords

Biomarkers; Cytokines; Human African Trypanosomiasis; Immune response; Sleeping sickness

Indexed keywords

BETA 2 MICROGLOBULIN; BINDING PROTEIN; CYTOKINE; GAMMA INTERFERON; GELATINASE B; IMMUNOGLOBULIN; IMMUNOGLOBULIN M; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; AFRICA SOUTH OF THE SAHARA; AFRICAN TRYPANOSOMIASIS; BLOOD SMEAR; CLINICAL FEATURE; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; ENDEMIC DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGY; INNATE IMMUNITY; LIMIT OF DETECTION; NONHUMAN; PATHOGENESIS; REVIEW; SENSITIVITY AND SPECIFICITY; TRYPANOSOMA BRUCEI RHODESIENSE;

EID: 84959111818     PISSN: 17101484     EISSN: 17101492     Source Type: Journal    
DOI: 10.1186/s13223-016-0113-5     Document Type: Review

References (109)

1. Welburn SC, Fèvre EM, Coleman PG, Odiit M, Maudlin I. Sleeping sickness: a tale of two diseases. Trends Parasitol. 2001;17(1):19-24.
2. Barrett MP, Burchmore RJ, Stich A, Lazzari JO, Frasch AC, Cazzulo JJ, et al. The trypanosomiases. Lancet. 2003;362(9394):1469-80.
3. Foulkes J. The six diseases WHO. Human trypanosomiasis in Africa. Br Med J. 1981;283(6300):1172-4.
4. Simarro PP, Cecchi G, Franco JR, Paone M, Diarra A, Ruiz-Postigo JA, et al. Estimating and mapping the population at risk of sleeping sickness. PLoS Negl Trop Dis. 2012;6(10):e1859. doi: 10.1371/journal.pntd.0001859.
5. Matemba LE, Fèvre EM, Kibona SN, Picozzi K, Cleaveland S, Shaw AP, et al. Quantifying the burden of rhodesiense sleeping sickness in Urambo District, Tanzania. PLoS Negl Trop Dis. 2010;4(11):e868.
6. Odiit M, Coleman P, Liu WC, McDermott J, Fevre E, Welburn S, et al. Quantifying the level of under-detection of Trypanosoma brucei rhodesiense sleeping sickness cases. Trop Med Int Health. 2005;10(9):840-9.
7. Kato CD, Nanteza A, Mugasa C, Edyelu A, Matovu E, Alibu VP. Clinical profiles, disease outcome and co-morbidities among T. b. rhodesiense sleeping sickness patients in Uganda. PLoS One. 2015;10(2):e0118370.
8. MacLean LM, Chisi JE, Odiit M, Gibson WC, Ferris V, Picozzi K, et al. Severity of human African trypanosomiasis in East Africa is associated with geographic location, parasite genotype, and host inflammatory cytokine response profile. Infect Immun. 2004;72(12):7040-4.
9. MacLean LM, Odiit M, Chisi JE, Kennedy PG, Sternberg JM. Focus-specific clinical profiles in human African trypanosomiasis caused by Trypanosoma brucei rhodesiense. PLoS Negl Trop Dis. 2010;4(12):e906.
10. Ormerod W. Taxonomy of the sleeping sickness trypanosomes. The Journal of parasitology. 1967:824-30.
11. Blum J, Neumayr A, Hatz C. Human African trypanosomiasis in endemic populations and travellers. Eur J Clin Microbiol Infect Dis. 2012;31(6):905-13.
12. Duggan AJ, Hutchinson MP. Sleeping sickness in Europeans: a review of 109 cases. J Trop Med Hyg. 1966;69(6):124-31.
13. MacLean LM, Odiit M, MacLeod A, Morrison L, Sweeney L, Cooper A, et al. Spatially and genetically distinct African Trypanosome virulence variants defined by host interferon-γ response. J Infect Dis. 2007;196(11):1620-8.
14. Sternberg JM, MacLean L. A spectrum of disease in human African trypanosomiasis: the host and parasite genetics of virulence. Parasitology. 2010;137(14):2007-15.
15. Sternberg JM, Rodgers J, Bradley B, MacLean L, Murray M, Kennedy PG. Meningoencephalitic African trypanosomiasis: brain IL-10 and IL-6 are associated with protection from neuro-inflammatory pathology. J Neuroimmunol. 2005;167(1):81-9.
16. Kennedy PG. Cytokines in central nervous system trypanosomiasis: cause, effect or both? Trans R Soc Trop Med Hyg. 2009;103(3):213-4.
17. Bakhiet M, Olsson T, Mhlanga J, Buscher P, Lycke N, van der Meide PH, et al. Human and rodent interferon-gamma as a growth factor for Trypanosoma brucei. Eur J Immunol. 1996;26(6):1359-64. doi: 10.1002/eji.1830260627.
18. Hertz CJ, Filutowicz H, Mansfield JM. Resistance to the African trypanosomes is IFN-gamma dependent. J immunol (Baltimore, Md: 1950). 1998;161(12):6775-83.
19. Kagira JM, Maina N, Njenga J, Karanja SM, Karori SM, Ngotho JM. Prevalence and types of coinfections in sleeping sickness patients in kenya (2000/2009). J Trop Med. 2011;2011:248914. doi: 10.1155/2011/248914.
20. Kuepfer I, Hhary EP, Allan M, Edielu A, Burri C, Blum JA. Clinical presentation of Tb rhodesiense sleeping sickness in second stage patients from Tanzania and Uganda. PLoS Negl Trop Dis. 2011;5(3):e968.
21. Gillet P, Maltha J, Hermans V, Ravinetto R, Bruggeman C, Jacobs J. Malaria rapid diagnostic kits: quality of packaging, design and labelling of boxes and components and readability and accuracy of information inserts. Malar J. 2011;10:39. doi: 10.1186/1475-2875-10-39.
22. Mitashi P, Hasker E, Lejon V, Kande V, Muyembe JJ, Lutumba P, et al. Human african trypanosomiasis diagnosis in first-line health services of endemic countries, a systematic review. PLoS Negl Trop Dis. 2012;6(11):e1919. doi: 10.1371/journal.pntd.0001919.
23. WHO. Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1998;881:1-114 (I-VI).
24. Brun R, Blum J, Chappuis F, Burri C. Human African trypanosomiasis. Lancet. 2010;375(9709):148-59.
25. Miezan TW, Meda AH, Doua F, Cattand P. Evaluation of the parasitologic technics used in the diagnosis of human Trypanosoma gambiense trypanosomiasis in the Ivory Coast. Bull soc Pathol Exot (1990). 1994;87(2):101-4.
26. Ancelle T, Paugam A, Bourlioux F, Merad A, Vigier JP. Detection of trypanosomes in blood by the Quantitative Buffy Coat (QBC) technique: experimental evaluation. Med Trop (Mars). 1997;57(3):245-8.
27. ® and miniature anion-exchange centrifugation techniques. Trans R Soc Trop Med Hyg. 1998;92(3):288-9.
28. Woo PT. The haematocrit centrifuge technique for the diagnosis of African trypanosomiasis. Acta Trop. 1970;27(4):384-6.
29. Woo PT. Evaluation of the haematocrit centrifuge and other techniques for the field diagnosis of human trypanosomiasis and filariasis. Acta Trop. 1971;28(3):298-303.
30. Lumsden W, Kimber C, Evans D, Doig S. Trypanosoma brucei: miniature anion-exchange centrifugation technique for detection of low parasitaemias: adaptation for field use. Trans R Soc Trop Med Hyg. 1979;73(3):312-7.
31. Camara M, Camara O, Ilboudo H, Sakande H, Kaboré J, N'Dri L, et al. Sleeping sickness diagnosis: use of buffy coats improves the sensitivity of the mini anion exchange centrifugation test. Trop Med Int Health. 2010;15(7):796-9.
32. Van Xong H, Vanhamme L, Chamekh M, Chimfwembe CE, Van Den Abbeele J, Pays A, et al. A VSG expression site-associated gene confers resistance to human serum in Trypanosoma rhodesiense. Cell. 1998;95(6):839-46.
33. De Greef C, Imberechts H, Matthyssens G, Van Meirvenne N, Hamers R. A gene expressed only in serum-resistant variants of Trypanosoma brucei rhodesiense. Mol Biochem Parasitol. 1989;36(2):169-76.
34. Radwanska M, Chamekh M, Vanhamme L, Claes F, Magez S, Magnus E, et al. The serum resistance-associated gene as a diagnostic tool for the detection of Trypanosoma brucei rhodesiense. Am J Trop Med Hyg. 2002;67(6):684-90.
35. Jamonneau V, Solano P, Garcia A, Lejon V, Dje N, Miezan T, et al. Stage determination and therapeutic decision in human African trypanosomiasis: value of polymerase chain reaction and immunoglobulin M quantification on the cerebrospinal fluid of sleeping sickness patients in Cote d'Ivoire. Trop Med Int Health. 2003;8(7):589-94.
36. Kuboki N, Inoue N, Sakurai T, Di Cello F, Grab DJ, Suzuki H, et al. Loop-mediated isothermal amplification for detection of African trypanosomes. J Clin Microbiol. 2003;41(12):5517-24.
37. Njiru ZK, Mikosza ASJ, Armstrong T, Enyaru JC, Ndung'u JM, Thompson ARC. Loop-mediated isothermal amplification (LAMP) method for rapid detection of Trypanosoma brucei rhodesiense. PLoS Negl Trop Dis. 2008;2(2):e147.
38. Mugasa CM, Laurent T, Schoone GJ, Kager PA, Lubega GW, Schallig HD. Nucleic acid sequence-based amplification with oligochromatography for detection of Trypanosoma brucei in clinical samples. J Clin Microbiol. 2009;47(3):630-5.
39. Deborggraeve S, Claes F, Laurent T, Mertens P, Leclipteux T, Dujardin J, et al. Molecular dipstick test for diagnosis of sleeping sickness. J Clin Microbiol. 2006;44(8):2884-9.
40. Amin DN, Ngoyi DM, Nhkwachi G-M, Palomba M, Rottenberg M, Büscher P, et al. Identification of stage biomarkers for human African trypanosomiasis. Am J Trop Med Hyg. 2010;82(6):983-90.
41. Hainard A, Tiberti N, Robin X, Lejon V, Ngoyi DM, Matovu E, et al. A combined CXCL10, CXCL8 and H-FABP panel for the staging of human African trypanosomiasis patients. PLoS Negl Trop Dis. 2009;3(6):e459.
42. Molina-Portela MP, Samanovic M, Raper J. Distinct roles of apolipoprotein components within the trypanosome lytic factor complex revealed in a novel transgenic mouse model. J Exp Med. 2008;205(8):1721-8.
43. Vanhollebeke B, Truc P, Poelvoorde P, Pays A, Joshi PP, Katti R, et al. Human Trypanosoma evansi infection linked to a lack of apolipoprotein L-I. N Engl J Med. 2006;355(26):2752-6.
44. Vanhollebeke B, Nielsen MJ, Watanabe Y, Truc P, Vanhamme L, Nakajima K, et al. Distinct roles of haptoglobin-related protein and apolipoprotein L-I in trypanolysis by human serum. Proc Natl Acad Sci USA. 2007;104(10):4118-23.
45. Pays E. The variant surface glycoprotein as a tool for adaptation in African trypanosomes. Microbes Infect. 2006;8(3):930-7.
46. Ferrante A, Allison A. Alternative pathway activation of complement by African trypanosomes lacking a glycoprotein coat. Parasite Immunol. 1983;5(5):491-8.
47. Black S, Hewett RS. Trypanosoma brucei variable surface antigen is released by degenerating parasites but not by actively dividing parasites. Parasite Immunol. 1982;4(4):233-44.
48. Dubois ME, Demick KP, Mansfield JM. Trypanosomes expressing a mosaic variant surface glycoprotein coat escape early detection by the immune system. Infect Immun. 2005;73(5):2690-7.
49. Magez S, Stijlemans B, Baral T, De Baetselier P. VSG-GPI anchors of African trypanosomes: their role in macrophage activation and induction of infection-associated immunopathology. Microbes Infect. 2002;4(9):999-1006.
50. Mansfield JM. Immunobiology of African trypanosomiasis. Cell Immunol. 1978;39(1):204-10.
51. Pentreath V. Trypanosomiasis and the nervous system: pathology and immunology. Trans R Soc Trop Med Hyg. 1995;89(1):9-15.
52. Lejon V, Büscher P, Magnus E, Moons A, Wouters I, Van Meirvenne N. A semi-quantitative ELISA for detection of Trypanosoma brucei gambiense specific antibodies in serum and cerebrospinal fluid of sleeping sickness patients. Acta Trop. 1998;69(2):151-64.
53. Magez S, Schwegmann A, Atkinson R, Claes F, Drennan M, De Baetselier P, et al. The role of B-cells and IgM antibodies in parasitemia, anemia, and VSG switching in Trypanosoma brucei-infected mice. PLoS Pathog. 2008;4(8):e1000122.
54. Reinitz DM, Mansfield JM. T-cell-independent and T-cell-dependent B-cell responses to exposed variant surface glycoprotein epitopes in trypanosome-infected mice. Infect Immun. 1990;58(7):2337-42.
55. Stijlemans B, Guilliams M, Raes G, Beschin A, Magez S, De Baetselier P. African trypanosomosis: from immune escape and immunopathology to immune intervention. Vet Parasitol. 2007;148(1):3-13.
56. Ngotho M, Kagira J, Jensen H, Karanja S, Farah I, Hau J. Immunospecific immunoglobulins and IL-10 as markers for Trypanosoma brucei rhodesiense late stage disease in experimentally infected vervet monkeys. Trop Med Int Health. 2009;14(7):736-47.
57. Hertz CJ, Mansfield JM. IFN-γ-dependent nitric oxide production is not linked to resistance in experimental African trypanosomiasis. Cell Immunol. 1999;192(1):24-32.
58. Hunter CA, Jennings FW, Kennedy PG, Murray M. Astrocyte activation correlates with cytokine production in central nervous system of Trypanosoma brucei brucei-infected mice. Lab Invest. 1992;67(5):635-42.
59. Kaushik RS, Uzonna JE, Zhang Y, Gordon JR, Tabel H. Innate resistance to experimental African trypanosomiasis: differences in cytokine (TNF-α, IL-6, IL-10 and IL-12) production by bone marrow-derived macrophages from resistant and susceptible mice. Cytokine. 2000;12(7):1024-34.
60. Maina N, Ngotho JM, Were T, Thuita JK, Mwangangi DM, Kagira JM, et al. Proinflammatory cytokine expression in the early phase of Trypanosoma brucei rhodesiense infection in vervet monkeys (Cercopithecus aethiops). Infect Immun. 2004;72(5):3063-5.
61. Namangala B, Noël W, De Baetselier P, Brys L, Beschin A. Relative contribution of interferon-γ and interleukin-10 to resistance to murine African trypanosomosis. J Infect Dis. 2001;183(12):1794-800.
62. Namangala B, De Baetselier P, Beschin A. Both type-I and type-II responses contribute to murine trypanotolerance. J Vet Med Sci. 2009;71(3):313-8.
63. Bucheton B, MacLeod A, Jamonneau V. Human host determinants influencing the outcome of Trypanosoma brucei gambiense infections. Parasite Immunol. 2011;33(8):438-47.
64. Rhind SG, Sabiston BH, Shek PN, Buguet A, Muanga G, Stanghellini A, et al. Effect of melarsoprol treatment on circulating IL-10 and TNF-α levels in human African trypanosomiasis. Clin Immunol Immunopathol. 1997;83(2):185-9.
65. Magez S, Stijlemans B, Radwanska M, Pays E, Ferguson MA, De Baetselier P. The glycosyl-inositol-phosphate and dimyristoylglycerol moieties of the glycosylphosphatidylinositol anchor of the trypanosome variant-specific surface glycoprotein are distinct macrophage-activating factors. J Immunol (Baltimore, Md: 1950). 1998;160(4):1949-56.
66. Magez S, Geuskens M, Beschin A, Del Favero H, Verschueren H, Lucas R, et al. Specific uptake of tumor necrosis factor-α is involved in growth control of Trypanosoma brucei. J Cell Biol. 1997;137(3):715-27.
67. Magez S, Radwanska M, Beschin A, Sekikawa K, De Baetselier P. Tumor necrosis factor alpha is a key mediator in the regulation of experimental Trypanosoma brucei infections. Infect Immun. 1999;67(6):3128-32.
68. Naessens J, Kitani H, Nakamura Y, Yagi Y, Sekikawa K, Iraqi F. TNF-a mediates the development of anaemia in a murine Trypanosoma brucei rhodesiense infection, but not the anaemia associated with a murine Trypanosoma congolense infection. Clin Exp Immunol. 2005;139(3):405-10.
69. Dauloue'd S, Bouteille B, Moynet D, Lemesre J, Buguet A, Cespuglio R, et al. Human macrophage tumor necrosis factor (TNF)-a production induced by Trypanosoma brucei gambiense and the Role of TNF-a in parasite control. J Infect Dis. 2001;183:988-91.
70. Amin DN, Vodnala SK, Masocha W, Sun B, Kristensson K, Rottenberg ME. Distinct toll-like receptor signals regulate cerebral parasite load and interferon α/β and tumor necrosis factor α-dependent t-cell infiltration in the brains of Trypanosoma brucei-Infected Mice. J Infect Dis. 2012;205(2):320-32. doi: 10.1093/infdis/jir734.
71. MacLean LM, Odiit M, Sternberg JM. Nitric oxide and cytokine synthesis in human African trypanosomiasis. J Infect Dis. 2001;184(8):1086-90.
72. Lejon V, Lardon J, Kenis G, Pinoges L, Legros D, Bisser S, et al. Interleukin (IL)-6, IL-8 and IL-10 in serum and CSF of Trypanosoma brucei gambiense sleeping sickness patients before and after treatment. Trans R Soc Trop Med Hyg. 2002;96(3):329-33.
73. Mabbott N, Coulson P, Smythies L, Wilson R, Sternberg J. African trypanosome infections in mice that lack the interferon-gamma receptor gene: nitric oxide-dependent and-independent suppression of T-cell proliferative responses and the development of anaemia. Immunology. 1998;94(4):476.
74. Olsson T, Bakhiet M, Edlund C, Höjeberg B, van der Meide PH, Kristensson K. Bidirectional activating signals between Trypanosoma brucei and CD8'+'T cells: A trypanosome-released factor triggers interferon-γ production that stimulates parasite growth. Eur J Immunol. 1991;21(10):2447-54.
75. Masocha W, Robertson B, Rottenberg ME, Mhlanga J, Sorokin L, Kristensson K. Cerebral vessel laminins and IFN-γ define Trypanosoma brucei brucei penetration of the blood-brain barrier. J Clin Invest. 2004;114(5):689.
76. MacLean LM, Reiber H, Kennedy PG, Sternberg JM. Stage progression and neurological symptoms in Trypanosoma brucei rhodesiense sleeping sickness: role of the CNS inflammatory response. PLoS Negl Trop Dis. 2012;6(10):e1857. doi: 10.1371/journal.pntd.0001857.
77. Pizarro TT, Cominelli F. Cloning IL-1 and the birth of a new era in cytokine biology. J Immunol. 2007;178(9):5411-2.
78. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood. 1990;75(1):40-7.
79. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519-50.
80. Ludigs K, Parfenov V, Du Pasquier RA, Guarda G. Type I IFN-mediated regulation of IL-1 production in inflammatory disorders. Cell Mol Life Sci. 2012;69(20):3395-418.
81. Argaw AT, Zhang Y, Snyder BJ, Zhao ML, Kopp N, Lee SC, et al. IL-1beta regulates blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program. J Immunol (Baltimore, Md: 1950). 2006;177(8):5574-84.
82. Quan N, He L, Lai W. Intraventricular infusion of antagonists of IL-1 and TNFα attenuates neurodegeneration induced by the infection of Trypanosoma brucei. J Neuroimmunol. 2003;138(1):92-8.
83. Quan N, Mhlanga JD, Whiteside MB, McCoy AN, Kristensson K, Herkenham M. Chronic overexpression of proinflammatory cytokines and histopathology in the brains of rats infected with Trypanosoma brucei. J Comp Neurol. 1999;414(1):114-30.
84. Wahl SM, McCartney-Francis N, Mergenhagen SE. Inflammatory and immunomodulatory roles of TGF-β. Immunol Today. 1989;10(8):258-61.
85. Espevik T, Figari IS, Shalaby MR, Lackides GA, Lewis GD, Shepard HM, et al. Inhibition of cytokine production by cyclosporin A and transforming growth factor β. J Exp Med. 1987;166(2):571-6.
86. Pedersen BK. The diseasome of physical inactivity-and the role of myokines in muscle-fat cross talk. J Physiol. 2009;587(23):5559-68.
87. Kushima Y, Hatanaka H. Interleukin-6 and leukemia inhibitory factor promote the survival of acetylcholinesterase-positive neurons in culture from embryonic rat spinal cord. Neurosci Lett. 1992;143(1):110-4.
88. Oka T, Oka K, Hosoi M, Hori T. Intracerebroventricular injection of interleukin-6 induces thermal hyperalgesia in rats. Brain Res. 1995;692(1):123-8.
89. Gadient RA, Otten UH. Interleukin-6 (IL-6)-a molecule with both beneficial and destructive potentials. Prog Neurobiol. 1997;52(5):379-90. doi: 10.1016/S0301-0082(97)00021-X.
90. Brett FM, Mizisin AP, Powell HC, Campbell IL. Evolution of neuropathologic abnormalities associated with blood-brain barrier breakdown in transgenic mice expressing lnterleukin-6 in astrocytes. J Neuropathol Exp Neurol. 1995;54(6):766-75.
91. Nyawira-Maranga D, Kagira JM, Kinyanjui CK, Muturi Karanja S, Wangari Maina N, Ngotho M. IL-6 is upregulated in late-stage disease in monkeys experimentally infected with Trypanosoma brucei rhodesiense. Clin Dev Immunol. 2013;2013:320509. doi: 10.1155/2013/320509.
92. MacLean LM, Odiit M, Sternberg JM. Intrathecal cytokine responses in Trypanosoma brucei rhodesiense sleeping sickness patients. Trans R Soc Trop Med Hyg. 2006;100(3):270-5.
93. Courtin D, Jamonneau V, Mathieu JF, Koffi M, Milet J, Yeminanga CS, et al. Comparison of cytokine plasma levels in human African trypanosomiasis. Trop Med Int Health. 2006;11(5):647-53.
94. Sabat R. IL-10 family of cytokines. Cytokine Growth Factor Rev. 2010;21(5):315-24.
95. Rousset F, Garcia E, Defrance T, Peronne C, Vezzio N, Hsu D-H, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA. 1992;89(5):1890-3.
96. Hunt NH, Grau GE. Cytokines: accelerators and brakes in the pathogenesis of cerebral malaria. Trends Immunol. 2003;24(9):491-9.
97. Sarciron M, Gherardi A. Cytokines involved in Toxoplasmic encephalitis. Scand J Immunol. 2000;52(6):534-43.
98. Atkinson AJ, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89-95.
99. Kennedy PG. Difficulties in diagnostic staging of human African trypanosomiasis. J Neuroparasitol. 2011;2:1-3.
100. Tiberti N, Matovu E, Hainard A, Enyaru JC, Lejon V, Robin X, et al. New biomarkers for stage determination in Trypanosoma brucei rhodesiense sleeping sickness patients. Clin Transl Med. 2013;2(1):1. doi: 10.1186/2001-1326-2-1.
101. Lejon V, Roger I, Ngoyi DM, Menten J, Robays J, N'Siesi FX, et al. Novel markers for treatment outcome in late-stage Trypanosoma brucei gambiense trypanosomiasis. Clin Infect Dis. 2008;47(1):15-22.
102. Kato CD, Alibu VP, Nanteza A, Mugasa CM, Matovu E. Interleukin (IL)-6 and IL-10 are up regulated in late stage Trypanosoma brucei rhodesiense sleeping sickness. PLoS Negl Trop Dis. 2015;9(6):e0003835. doi: 10.1371/journal.pntd.0003835.
103. Courtioux B, Pervieux L, Vatunga G, Marin B, Josenando T, Jauberteau-Marchan MO, et al. Increased CXCL-13 levels in human African trypanosomiasis meningo-encephalitis. Trop Med Int Health. 2009;14(5):529-34.
104. Hainard A, Tiberti N, Robin X, Ngoyi DM, Matovu E, Enyaru JC, et al. Matrix metalloproteinase-9 and intercellular adhesion molecule 1 are powerful staging markers for human African trypanosomiasis. Trop Med Int Health. 2011;16(1):119-26.
105. Tiberti N, Hainard A, Lejon V, Courtioux B, Matovu E, Enyaru JC, et al. Cerebrospinal fluid neopterin as marker of the meningo-encephalitic stage of Trypanosoma brucei gambiense sleeping sickness. PLoS One. 2012;7(7):e40909.
106. Tiberti N, Hainard A, Lejon V, Robin X, Ngoyi DM, Turck N, et al. Discovery and verification of osteopontin and β-2-microglobulin as promising markers for staging human African trypanosomiasis. Mol Cell Proteomics. 2010;9(12):2783-95.
107. Sternberg JM, Mitchell JA. Plasma neuronal specific enolase: a potential stage diagnostic marker in human African trypanosomiasis. Trans R Soc Trop Med Hyg. 2014;108(7):449-52. doi: 10.1093/trstmh/tru065.
108. da Costa AG, Antonelli LR, Costa PA, Pimentel JP, Garcia NP, Tarrago AM, et al. The robust and modulated biomarker network elicited by the Plasmodium vivax infection is mainly mediated by the IL-6/IL-10 axis and is associated with the parasite load. J Immunol Res. 2014;2014:318250. doi: 10.1155/2014/318250.
109. Lucas R, Magez S, Songa B, Darji A, Hamers R, De Baetselier P. A role for TNF during African trypanosomiasis: involvement in parasite control immunosuppression and pathology. Res Immunol. 1993;144(5):370-6.